Recent Posts by admin
sphingotec, LLC, a developer of predictive diagnostic tests for cancer, cardiovascular diseases and kidney function, today announced the results of a survey gauging women’s understanding of breast cancer risk factors and their perceptions of common breast cancer screening methods. The survey was conducted in conjunction with a national, independent health information resource for women, and…Read more
Biotech company to present how biomarkers improve breast cancer risk prediction in women under hormone replacement therapy. Cambridge, Mass. – Feb. 4, 2015 – sphingotec LLC announced today that the findings from its research seeking to improve breast cancer risk stratification for guiding hormone replacement therapy has been selected for presentation at the 14th annual…Read more
GeneNews/IDL will be first U.S. laboratory to offer sphingotec’s innovative breast cancer risk tests. Cambridge, Mass. – October 14, 2014 – sphingotec GmbH, headquartered in Hennigsdorf, Germany with U.S. operations in Cambridge, Massachusetts, today announced that it has out-licensed two of its biomarker assays—sphingotest® pro-NT and sphingotest® pro-ENK—to GeneNews Limited (TSX:GEN). The biomarker assays will…Read more
Recent Comments by admin
No comments by admin yet.